Existing BAX shareholders will receive 1 (tax-free) share of BXLT for each share of BAX; after the separation, BAX will retain a 19.5% stake in BXLT.
I’ve posted a few times about BXLT recently (e.g. the slide set in #msg-113807038 and the quiz in #msg-113974752 [solved by ‘genisi’]). BXLT will be the global leader in the treatment of hemophilia with an established portfolio and two gene-therapy product candidates (one in phase-1 and one preclinical) for hemophilia A and B, respectively.
BXLT will remain one of the top-3 global companies in IVIG and plasma-derived therapeutics. Further, BAX will have two FoB programs: one for Enbrel (partnered with CHRS) and one for Humira (partnered with MNTA).
BXLT will also have an uninspiring (IMO) presence in oncology, derived from two recent acquisitions (#msg-113565100, #msg-111442999). The move into oncology was made to enhance investor interest, but I think it will end up backfiring.
The remaining BAX (after the BXLT spin-off) will be highly leveraged to dialysis, and hence will be a strong play on the diabetes epidemic consequent to ‘The Global Demographic Tailwind’ (#msg-106316378, #msg-82247513).
Disclosure: No current position.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.